Previous close | 5.5150 |
Open | 4.5492 |
Bid | 0.0000 x N/A |
Ask | 0.0000 x N/A |
Day's range | 4.4906 - 4.5492 |
52-week range | 2.2672 - 8.0965 |
Volume | |
Avg. volume | 817 |
Market cap | N/A |
Beta (5Y monthly) | 1.78 |
PE ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
Bristol Myers, Moderna, 2seventy bio, Amylyx Pharmaceuticals and Syros Pharmaceuticals are part of the Zacks top Analyst Blog.
The FDA bestows a Fast Track Designation to Syros' (SYRS) pipeline candidate, tamibarotene, in combination with venetoclax and azacitidine to treat newly diagnosed acute myeloid leukemia. Stock rises.
Syros Pharmaceuticals (SYRS) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.